Published in Antimicrob Agents Chemother on May 23, 2016
Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration. Antimicrob Agents Chemother (2017) 0.75
A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. Infect Dis Ther (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (2015) 9.40
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med (2016) 3.82
A vaginal fluid simulant. Contraception (1999) 3.36
Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm (2009) 2.79
No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis (2015) 2.40
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol (1995) 2.00
Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des (2004) 1.97
Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol (2009) 1.76
Baseline dimensions of the human vagina. Hum Reprod (2006) 1.59
The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception (1999) 1.50
Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol (2000) 1.44
Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One (2013) 1.43
Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev (2002) 1.42
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use. AIDS Behav (2012) 1.35
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
AIDS. Turning the tide against HIV. Science (2011) 1.21
Surface area of the human vagina as measured from vinyl polysiloxane casts. Gynecol Obstet Invest (2003) 1.20
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J Clin Microbiol (2010) 1.17
Is resistance futile? Curr Drug Targets Infect Disord (2003) 1.14
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother (2012) 1.11
Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS (2012) 1.10
Dosage frequency and drug-compliance behaviour--a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol (1991) 1.00
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99
Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model. Antimicrob Agents Chemother (2013) 0.97
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93
Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv Transl Res (2015) 0.89
Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis. J Pharm Biomed Anal (2014) 0.85
Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85
An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Int J Pharm (2015) 0.84
Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples. J Chromatogr B Analyt Technol Biomed Life Sci (2016) 0.76
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93
MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis (2016) 0.78
Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. Antimicrob Agents Chemother (2017) 0.76